← All Cervomed INC filings

Cervomed INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
CRVO
Cervomed INC
10-K: CervoMed Reports 2025 Losses, Advances DLB Drug to Phase 3
CervoMed Inc. reported a significant net loss of $27.0 million for 2025, while advancing its lead drug candidate, neflamapimod, to a planned Phase 3 trial for Dementia with Lewy Bodies, despite ongoing funding needs.
NASDAQ
CRVO
Cervomed INC
10-K: CervoMed Inc. Reports Promising Phase 2b Trial Results for DLB Treatment; Eyes Phase 3 Initiation in 2026
CervoMed Inc. announces positive 16-week extension data from its RewinD-LB Trial, signaling potential advancement of neflamapimod as a treatment for Dementia with Lewy Bodies (DLB) and setting the stage for a Phase 3 trial.
NASDAQ
CRVO
Cervomed INC
10-K: CervoMed Inc. Files 10-K, Highlights Progress in DLB Treatment
CervoMed Inc.'s 10-K filing details the company's focus on developing neflamapimod for age-related neurological disorders, particularly Dementia with Lewy Bodies (DLB), and its ongoing Phase 2b clinical trial.